302:
skeletal muscle and mesentery. The research group also demonstrated that serum proteins other than albumin and orosomucoid are less important for the maintenance of normal capillary permeability. In 2003, he and
Jeansson conducted the first functional study of glomerular size and charge selectivity in mice to explore the controversial issue of glomerular permselectivity in animals exposed to glucosaminoglycan-degrading enzymes, hyaluronidase, and heparinase. It was found out that polysaccharide-rich structures, such as the endothelial cell coat are key components in the glomerular barrier.
306:
ionic strength, causing proteinuria. He studied the interaction between podocytes, the endothelial cells, and their ESL, and presented conditions with disturbed communication causing proteinuria. In 2014, together with colleagues in New York, he confirmed the reciprocal crosstalk between podocytes and endothelial cells in a coculture system, and further highlighted that segmental glomerulosclerosis develops as a result of podocyte-endothelial crosstalk mediated by EDN1/EDNRA-dependent mitochondrial dysfunction.
313:, Haraldsson’s group introduced HPLC-ESI-MS/MS method which has the ability to monitor orellanine at low concentrations within the therapeutic interval in blood serum. Later on, the research group provided long-term clinical outcomes for patients poisoned by the fungal nephrotoxin orellanine. Their studies also suggested the usage of orellanine in terms of eliminating human renal cancer carcinomas with its highly organ-specific cytotoxic properties.
31:
293:
application of plasma glycoprotein orosomucoid in regulating the dynamic properties of the glomerular capillary wall by reducing the permeability towards macromolecules. He developed a computer model for individualized therapy of patients with PD, and regarded total pore area over diffusion distance (A(0)/Deltax) to be the significant parameter to describe exchange across the peritoneal membrane.
222:) of Physiology at Gothenburg University till 2000, and as a Professor and Chair of Nephrology till 2015. During this time period, he also held concurrent appointments as Researcher in integrative physiology, as Department Head, as Director of the university board, and as Vice Dean for the Sahlgrenska academy at the University of Gothenburg. Moreover, he chaired several
301:
Haraldsson’s research group published a series of papers focused on the understanding of the glomerular barrier, its properties, and the role of its individual components. In a paper published in 1992, he highlighted the role of orosomucoid in terms of maintenance of normal capillary permeability in
305:
Building on work by
William Deen, Haraldsson developed the first unified heterogenous charged fiber model, while incorporating the effects of solute size and charge. He along with co-workers, also demonstrated how the structure of the ESL can be affected by enzymes, ischemia-reperfusion injury, or
335:
Nashan, B., Tedesco, H., Van den Hoogen, M. W., Berger, S. P., Cibrik, D., Mulgaonkar, S., ... & Witzke, O. (2018). CD40 inhibition with CFZ533-a new, fully human, non-depleting, Fc silent mAB-improves renal allograft function while demonstrating comparable efficacy vs. tacrolimus in de-novo
288:
Haraldsson introduced several models and techniques to explore the permeability in different organs. Together with Bengt Rippe, he developed the two-pore model for solute exchange, and later the three-pore model for fluid and solute exchange across capillary walls. They provided new insights
292:
Haraldsson is also the one to discover the role of orosomucoid in terms of maintenance of normal capillary permselectivity. He regarded the endothelial cell surface layer (ESL) to be the key contributor in the context of the glomerular barrier. In a study conducted in 1993, he discussed the
350:
Khramova, A., Boi, R., Fridén, V., Granqvist, A. B., Nilsson, U., Tenstad, O., ... & Nyström, J. (2021). Proteoglycans contribute to the functional integrity of the glomerular endothelial cell surface layer and are regulated in diabetic kidney disease. Scientific reports, 11(1),
343:
Webb, N., Haraldsson, B., Schubart, A., Milojevic, J., End, P., Holbro, T., & Junge, G. (2020). MO042 LNP023: A NOVEL ORAL COMPLEMENT ALTERNATIVE PATHWAY FACTOR B INHIBITOR FOR THE TREATMENT OF GLOMERULAR DISEASE. Nephrology
Dialysis Transplantation, 35(Supplement_3),
339:
Nystrom, J., Khramova, A., Haraldsson, B., & Ebefors, K. (2019). SAT-125 Proteoglycans are glomerular endothelial glycocalyx components playing a major role in permselectivity and prevention of proteinuria. Kidney
International Reports, 4(7),
240:
In 2014, Haraldsson held appointment as an
Executive Director at Novartis Institute of Biomedical research (NIBR). After working there as a translational medicine expert in the ATI department for 3 years, he became Global Program Head in
1245:
Buvall, L.; Hedman, H.; Khramova, A.; Najar, D.; Bergwall, L.; Ebefors, K.; Sihlbom, C.; Lundstam, S.; Herrmann, A.; Wallentin, H.; Roos, E.; Nilsson, U. A.; Johansson, M.; Törnell, J.; Haraldsson, B.; Nyström, J. (2017).
289:
regarding fenestrated capillaries of the pancreatic, and salivary glands which were considered to ‘leak’ proteins. They demonstrated that these capillaries had similar permselectivity as continuous capillaries.
187:, he started medical school at the University of Gothenburg in 1976. There he performed his graduate work in physiology to receive his M.D. in 1982 and Ph.D in 1986, under the supervision of Bengt Rippe and
226:’s expert panels, and served as scientific secretary of the Gothenburg Medical Association. From 2011 till 2014, he was a visiting professor of medicine at Mount Sinai School of medicine in New York.
839:"Importance of molecular charge for the passage of endogenous macromolecules across continuous capillary walls, studied by serum clearance of lactate dehydrogenase (LDH) isoenzymes"
1067:
Daehn, I.; Casalena, G.; Zhang, T.; Shi, S.; Fenninger, F.; Barasch, N.; Yu, L.; d'Agati, V.; Schlondorff, D.; Kriz, W.; Haraldsson, B.; Bottinger, E. P. (2014).
1316:
264:
Haraldsson has focused his research on kidney disease, with particular attention on the properties of the glomerular barrier crucial for whole-body
347:
Ballermann, B. J., Nystrom, J., & Haraldsson, B. (2021). The glomerular endothelium restricts albumin filtration. Frontiers in
Medicine, 2402.
399:"Physiological studies of macromolecular transport across capillary walls. Studies on continuous capillaries in rat skeletal muscle"
878:"Serum factors other than albumin are needed for the maintenance of normal capillary permselectivity in rat hindlimb muscle"
215:
as
Resident Physician. Afterward, he served there as an attending physician till 2000, and as senior consultant till 2014.
164:
199:
During his doctoral studies, Haraldsson began his clinical career as a part-time physician in emergency rooms in Borås,
718:"Addition of purified orosomucoid preserves the glomerular permeability for albumin in isolated perfused rat kidneys"
980:"Dynamic alterations of glomerular charge density in fixed rat kidneys suggest involvement of endothelial cell coat"
915:
638:"Orosomucoid as one of the serum components contributing to normal capillary permselectivity in rat skeletal muscle"
280:. Currently, Haraldsson has been working on the development of a new drug that could cure widespread kidney cancer.
1116:
Nilsson, U. A.; Nyström, J.; Buvall, L.; Ebefors, K.; Björnson-Granqvist, A.; Holmdahl, J.; Haraldsson, B. (2008).
1118:"The fungal nephrotoxin orellanine simultaneously increases oxidative stress and down-regulates cellular defenses"
480:"Fluid and protein fluxes across small and large pores in the microvasculature. Application of two-pore equations"
212:
1311:
1155:
Herrmann, Anders; Hedman, Heidi; Rosén, Johan; Jansson, Daniel; Haraldsson, Börje; Hellenäs, Karl-Erik (2012).
168:
431:
931:"Glomerular size and charge selectivity in the mouse after exposure to glucosaminoglycan-degrading enzymes"
1194:
Hedman, Heidi; Holmdahl, Johan; Mölne, Johan; Ebefors, Kerstin; Haraldsson, Börje; Nyström, Jenny (2017).
1069:"Endothelial mitochondrial oxidative stress determines podocyte depletion in segmental glomerulosclerosis"
191:. His dissertation was titled "Physiological studies of macromolecular transport across capillary walls".
598:
237:. As he returned to Sweden in 2022, he rejoined the University of Gothenburg as Professor of Physiology.
675:
Fridén, V.; Oveland, E.; Tenstad, O.; Ebefors, K.; Nyström, J.; Nilsson, U. A.; Haraldsson, B. (2011).
464:
211:. He completed his internship at Mölndals hospital, Sweden in 1989, and was subsequently appointed by
253:(IHD) in 2018. In 2022, he left Novartis to become CSO, and four months later CEO, at Oncorena AB.
223:
160:
85:
256:
Haraldsson is the
Founder of three consultancy firms: Hand i Hand, Soinial AB, and Creorena AB.
1301:
1030:"Mild renal ischemia-reperfusion reduces charge and size selectivity of the glomerular barrier"
277:
184:
383:
1306:
8:
916:"Glomerular permselectivity is dependent on adequate serum concentrations of orosomucoid"
148:
95:
1133:
369:
1272:
1247:
1222:
1196:"Long-term clinical outcome for patients poisoned by the fungal nephrotoxin orellanine"
1195:
1093:
1068:
1007:
978:
Ciarimboli, G.; Hjalmarsson, C.; Bökenkamp, A.; Schurek, H. J.; Haraldsson, B. (2003).
960:
947:
930:
893:
854:
733:
653:
495:
798:"Dynamic changes of the total pore area available for peritoneal exchange in children"
1277:
1227:
1176:
1137:
1098:
1049:
999:
952:
897:
858:
819:
778:
737:
698:
657:
618:
614:
579:
538:
499:
410:
1028:
Andersson, M.; Nilsson, U.; Hjalmarsson, C.; Haraldsson, B.; Nyström, J. S. (2007).
1011:
1267:
1259:
1217:
1207:
1168:
1129:
1088:
1080:
1041:
991:
964:
942:
889:
850:
809:
768:
729:
688:
649:
610:
569:
530:
491:
534:
1045:
995:
188:
599:"Fenestrated capillaries in the connective tissues of the periodontal ligament"
152:
107:
1263:
1212:
283:
1295:
677:"The glomerular endothelial cell coat is essential for glomerular filtration"
519:"Transport of macromolecules across microvascular walls: the two-pore theory"
296:
1156:
1117:
1029:
979:
200:
1281:
1231:
1180:
1141:
1102:
1053:
1003:
956:
877:
838:
823:
717:
702:
637:
518:
479:
398:
273:
269:
901:
862:
782:
741:
661:
622:
583:
542:
503:
414:
325:
2009 - Recipient of "Guldtackan" for contributions to the
Medical Students
204:
814:
797:
265:
250:
234:
773:
756:
574:
557:
693:
676:
450:
310:
246:
242:
156:
155:. He is the Chief Executive Officer at Oncorena AB, and a Professor of
1172:
1084:
1027:
977:
757:"Assessing the peritoneal dialysis capacities of individual patients"
1157:"Analysis of the mushroom nephrotoxin orellanine and its glucosides"
230:
30:
336:
CNI-free kidney transplant recipients. Transplantation, 102, S366.
180:
54:
208:
229:
In 2015, Haraldsson resigned his clinical professorship to join
219:
1248:"Orellanine specifically targets renal clear cell carcinoma"
558:"Computer simulations of peritoneal fluid transport in CAPD"
1115:
674:
284:
Novel techniques to assess permeability in different organs
183:. After completing his early education in a high school at
1193:
1154:
297:
Understanding of the glomerular barrier and its components
1244:
322:
1999 - High
Pedagogical Award, University of Gothenburg
1066:
836:
597:
Moxham, B.J.; Shore, R.C.; Berkovitz, B.K.B. (1985).
555:
451:"Njurprofessorn Börje Haraldsson tillbaka i Göteborg"
596:
218:
Haraldsson was appointed as an associate professor (
795:
928:
715:
1293:
1034:American Journal of Physiology. Renal Physiology
984:American Journal of Physiology. Renal Physiology
875:
635:
516:
477:
1317:Academic staff of the University of Gothenburg
837:Haraldsson, B.; Ekholm, C.; Rippe, B. (1983).
556:Rippe, B.; Stelin, G.; Haraldsson, B. (1991).
268:and survival. His clinical expertise includes
935:Journal of the American Society of Nephrology
802:Journal of the American Society of Nephrology
370:"Börje Haraldsson - University of Gothenburg"
432:"Oncorena appoints Chief Scientific Officer"
403:Acta Physiologica Scandinavica. Supplementum
179:Haraldsson was born on October 14, 1957, in
174:
754:
396:
29:
1271:
1221:
1211:
1092:
946:
813:
772:
692:
573:
329:
1294:
1023:
1021:
796:Fischbach, M.; Haraldsson, B. (2001).
384:"ASN Congratulates the FASN Inductees"
1073:The Journal of Clinical Investigation
929:Jeansson, M.; Haraldsson, B. (2003).
716:Johnsson, E.; Haraldsson, B. (1993).
445:
443:
441:
426:
424:
316:
1134:10.1016/j.freeradbiomed.2008.01.017
1122:Free Radical Biology & Medicine
1018:
165:American Society of Transplantation
13:
948:10.1097/01.asn.0000072742.02714.6e
894:10.1111/j.1748-1716.1985.tb07609.x
876:Haraldsson, B.; Rippe, B. (1985).
855:10.1111/j.1748-1716.1983.tb07186.x
734:10.1111/j.1748-1716.1993.tb09466.x
654:10.1111/j.1748-1716.1987.tb08047.x
636:Haraldsson, B.; Rippe, B. (1987).
517:Rippe, B.; Haraldsson, B. (1994).
496:10.1111/j.1748-1716.1987.tb08257.x
478:Rippe, B.; Haraldsson, B. (1987).
438:
421:
390:
14:
1328:
1238:
1187:
1148:
1109:
1060:
971:
922:
908:
869:
830:
789:
748:
709:
668:
629:
590:
465:"BBB seminar: Börje Haraldsson"
213:Sahlgrenska university hospital
882:Acta Physiologica Scandinavica
843:Acta Physiologica Scandinavica
722:Acta Physiologica Scandinavica
642:Acta Physiologica Scandinavica
549:
510:
484:Acta Physiologica Scandinavica
471:
457:
376:
362:
309:While focusing his studies on
169:American Society of Nephrology
159:in Sahlgrenska Academy at the
1:
535:10.1152/physrev.1994.74.1.163
355:
163:. He is also a Fellow of the
615:10.1016/0026-2862(85)90043-3
7:
1161:Journal of Natural Products
1046:10.1152/ajprenal.00152.2006
996:10.1152/ajprenal.00227.2001
276:, clinical nephrology, and
259:
16:Swedish Physician-scientist
10:
1333:
1264:10.18632/oncotarget.19555
1213:10.1186/s12882-017-0533-6
194:
138:
128:
121:
113:
102:
91:
81:
69:
61:
37:
28:
21:
224:Swedish Research Council
175:Early life and education
161:University of Gothenburg
134:University of Gothenburg
86:University of Gothenburg
755:Haraldsson, B. (1995).
397:Haraldsson, B. (1986).
603:Microvascular Research
278:chronic kidney failure
151:known for his work on
1312:Swedish nephrologists
523:Physiological Reviews
330:Selected publications
815:10.1681/ASN.V1271524
761:Kidney International
681:Kidney International
562:Kidney International
1258:(53): 91085–91098.
774:10.1038/ki.1995.169
575:10.1038/ki.1991.216
149:Physician-scientist
96:Physician-scientist
694:10.1038/ki.2011.58
434:. 5 February 2022.
1173:10.1021/np300135k
1167:(10): 1690–1696.
687:(12): 1322–1330.
317:Awards and honors
185:Bäckängsgymnasiet
142:
141:
123:Scientific career
75:Boerje Haraldsson
1324:
1286:
1285:
1275:
1242:
1236:
1235:
1225:
1215:
1191:
1185:
1184:
1152:
1146:
1145:
1128:(8): 1562–1569.
1113:
1107:
1106:
1096:
1085:10.1172/JCI71195
1079:(4): 1608–1621.
1064:
1058:
1057:
1025:
1016:
1015:
975:
969:
968:
950:
941:(7): 1756–1765.
926:
920:
919:
912:
906:
905:
873:
867:
866:
834:
828:
827:
817:
808:(7): 1524–1529.
793:
787:
786:
776:
767:(4): 1187–1198.
752:
746:
745:
713:
707:
706:
696:
672:
666:
665:
633:
627:
626:
594:
588:
587:
577:
553:
547:
546:
514:
508:
507:
475:
469:
468:
461:
455:
454:
447:
436:
435:
428:
419:
418:
394:
388:
387:
380:
374:
373:
366:
167:(FAST), and the
145:Börje Haraldsson
117:Karin Haraldsson
77:Borje Haraldsson
73:Börje Haraldsson
70:Other names
51:
48:October 14, 1957
47:
45:
33:
23:Börje Haraldsson
19:
18:
1332:
1331:
1327:
1326:
1325:
1323:
1322:
1321:
1292:
1291:
1290:
1289:
1243:
1239:
1192:
1188:
1153:
1149:
1114:
1110:
1065:
1061:
1026:
1019:
976:
972:
927:
923:
914:
913:
909:
874:
870:
835:
831:
794:
790:
753:
749:
714:
710:
673:
669:
634:
630:
595:
591:
554:
550:
515:
511:
476:
472:
463:
462:
458:
449:
448:
439:
430:
429:
422:
395:
391:
382:
381:
377:
368:
367:
363:
358:
332:
319:
299:
286:
262:
197:
177:
133:
82:Alma mater
76:
74:
57:
52:
49:
43:
41:
24:
17:
12:
11:
5:
1330:
1320:
1319:
1314:
1309:
1304:
1288:
1287:
1237:
1200:BMC Nephrology
1186:
1147:
1108:
1059:
1040:(6): F1802-9.
1017:
990:(4): F722-30.
970:
921:
907:
888:(4): 427–436.
868:
849:(1): 123–130.
829:
788:
747:
708:
667:
648:(1): 127–135.
628:
609:(1): 116–124.
589:
568:(2): 315–325.
548:
529:(1): 163–219.
509:
490:(3): 411–428.
470:
456:
437:
420:
389:
375:
360:
359:
357:
354:
353:
352:
348:
345:
344:gfaa140-MO042.
341:
337:
331:
328:
327:
326:
323:
318:
315:
298:
295:
285:
282:
261:
258:
196:
193:
176:
173:
153:kidney disease
140:
139:
136:
135:
130:
126:
125:
119:
118:
115:
111:
110:
108:kidney disease
104:
103:Known for
100:
99:
98:, and academic
93:
89:
88:
83:
79:
78:
71:
67:
66:
63:
59:
58:
53:
39:
35:
34:
26:
25:
22:
15:
9:
6:
4:
3:
2:
1329:
1318:
1315:
1313:
1310:
1308:
1305:
1303:
1302:Living people
1300:
1299:
1297:
1283:
1279:
1274:
1269:
1265:
1261:
1257:
1253:
1249:
1241:
1233:
1229:
1224:
1219:
1214:
1209:
1205:
1201:
1197:
1190:
1182:
1178:
1174:
1170:
1166:
1162:
1158:
1151:
1143:
1139:
1135:
1131:
1127:
1123:
1119:
1112:
1104:
1100:
1095:
1090:
1086:
1082:
1078:
1074:
1070:
1063:
1055:
1051:
1047:
1043:
1039:
1035:
1031:
1024:
1022:
1013:
1009:
1005:
1001:
997:
993:
989:
985:
981:
974:
966:
962:
958:
954:
949:
944:
940:
936:
932:
925:
917:
911:
903:
899:
895:
891:
887:
883:
879:
872:
864:
860:
856:
852:
848:
844:
840:
833:
825:
821:
816:
811:
807:
803:
799:
792:
784:
780:
775:
770:
766:
762:
758:
751:
743:
739:
735:
731:
727:
723:
719:
712:
704:
700:
695:
690:
686:
682:
678:
671:
663:
659:
655:
651:
647:
643:
639:
632:
624:
620:
616:
612:
608:
604:
600:
593:
585:
581:
576:
571:
567:
563:
559:
552:
544:
540:
536:
532:
528:
524:
520:
513:
505:
501:
497:
493:
489:
485:
481:
474:
466:
460:
452:
446:
444:
442:
433:
427:
425:
416:
412:
408:
404:
400:
393:
385:
379:
371:
365:
361:
349:
346:
342:
338:
334:
333:
324:
321:
320:
314:
312:
307:
303:
294:
290:
281:
279:
275:
271:
267:
257:
254:
252:
248:
244:
238:
236:
232:
227:
225:
221:
216:
214:
210:
206:
202:
192:
190:
186:
182:
181:Borås, Sweden
172:
170:
166:
162:
158:
154:
150:
147:is a Swedish
146:
137:
131:
127:
124:
120:
116:
112:
109:
105:
101:
97:
94:
92:Occupation(s)
90:
87:
84:
80:
72:
68:
64:
60:
56:
55:Borås, Sweden
50:(age 66)
40:
36:
32:
27:
20:
1255:
1251:
1240:
1203:
1199:
1189:
1164:
1160:
1150:
1125:
1121:
1111:
1076:
1072:
1062:
1037:
1033:
987:
983:
973:
938:
934:
924:
910:
885:
881:
871:
846:
842:
832:
805:
801:
791:
764:
760:
750:
725:
721:
711:
684:
680:
670:
645:
641:
631:
606:
602:
592:
565:
561:
551:
526:
522:
512:
487:
483:
473:
459:
406:
402:
392:
378:
364:
308:
304:
300:
291:
287:
274:hemodialysis
270:hypertension
263:
255:
239:
228:
217:
198:
189:Björn Folkow
178:
144:
143:
129:Institutions
122:
1307:1957 births
266:homeostasis
251:dermatology
235:Switzerland
132:Oncorena AB
62:Nationality
1296:Categories
1252:Oncotarget
1206:(1): 121.
728:(1): 1–8.
356:References
311:orellanine
247:hepatology
243:immunology
201:Vänersborg
157:Physiology
44:1957-10-14
205:Bäckefors
1282:29207627
1232:28372584
1181:23046414
1142:18279679
1103:24590287
1054:17376766
1012:23427869
1004:12812917
957:12819235
824:11423582
703:21412215
409:: 1–40.
260:Research
231:Novartis
171:(FASN).
106:work on
1273:5710908
1223:5379567
1094:3973074
965:7501308
902:3993401
863:6858700
783:7783418
742:8452035
662:3565039
623:4021834
584:1942781
543:8295933
504:3321914
415:3466511
209:Lysekil
65:Swedish
1280:
1270:
1230:
1220:
1179:
1140:
1101:
1091:
1052:
1010:
1002:
963:
955:
900:
861:
822:
781:
740:
701:
660:
621:
582:
541:
502:
413:
220:docent
207:, and
195:Career
114:Spouse
1008:S2CID
961:S2CID
351:1-12.
1278:PMID
1228:PMID
1177:PMID
1138:PMID
1099:PMID
1050:PMID
1000:PMID
953:PMID
898:PMID
859:PMID
820:PMID
779:PMID
738:PMID
699:PMID
658:PMID
619:PMID
580:PMID
539:PMID
500:PMID
411:PMID
340:S57.
249:and
38:Born
1268:PMC
1260:doi
1218:PMC
1208:doi
1169:doi
1130:doi
1089:PMC
1081:doi
1077:124
1042:doi
1038:292
992:doi
988:285
943:doi
890:doi
886:123
851:doi
847:117
810:doi
769:doi
730:doi
726:147
689:doi
650:doi
646:129
611:doi
570:doi
531:doi
492:doi
488:131
407:553
233:in
1298::
1276:.
1266:.
1254:.
1250:.
1226:.
1216:.
1204:18
1202:.
1198:.
1175:.
1165:75
1163:.
1159:.
1136:.
1126:44
1124:.
1120:.
1097:.
1087:.
1075:.
1071:.
1048:.
1036:.
1032:.
1020:^
1006:.
998:.
986:.
982:.
959:.
951:.
939:14
937:.
933:.
896:.
884:.
880:.
857:.
845:.
841:.
818:.
806:12
804:.
800:.
777:.
765:47
763:.
759:.
736:.
724:.
720:.
697:.
685:79
683:.
679:.
656:.
644:.
640:.
617:.
607:30
605:.
601:.
578:.
566:40
564:.
560:.
537:.
527:74
525:.
521:.
498:.
486:.
482:.
440:^
423:^
405:.
401:.
272:,
245:,
203:,
46:)
1284:.
1262::
1256:8
1234:.
1210::
1183:.
1171::
1144:.
1132::
1105:.
1083::
1056:.
1044::
1014:.
994::
967:.
945::
918:.
904:.
892::
865:.
853::
826:.
812::
785:.
771::
744:.
732::
705:.
691::
664:.
652::
625:.
613::
586:.
572::
545:.
533::
506:.
494::
467:.
453:.
417:.
386:.
372:.
42:(
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.
